Biodiversity and chemodiversity: Future perspectives in bioprospecting

Current Drug Targets

Volumn 12, Issue 11, 2011, Pages 1515-1530

  Ramesha, B T ^a   Gertsch, Jürg ^b   Ravikanth, G ^a,c   Priti, V ^a   Ganeshaiah, K N ^a,c   Uma Shaanker, R ^a,c  

^a UNIVERSITY OF AGRICULTURAL SCIENCES   (India)

^b UNIVERSITY OF BERN   (Switzerland)

^c ASHOKA TRUST FOR RESEARCH IN ECOLOGY AND THE ENVIRONMENT   (India)

Author keywords

Biodiversity; Bioprospecting; Chemodiversity; Data mining; Evolutionary rationale; Phylogenetic rationale; Search strategies; Traditional knowledge

Indexed keywords

10 DEACETYLBACCATIN III; ALKALOID DERIVATIVE; ALLOFERON 2; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BACCATIN III; CAMPTOTHECIN; COLCHICINE; DENTIGERUMYCIN; DIGITALIS GLYCOSIDE; IRIDOID; MEVINOLIN; OUABAIN; PACLITAXEL; QUININE; STROPHANTHIN; TERPENE DERIVATIVE; UNCLASSIFIED DRUG;

AYURVEDA; BIODIVERSITY; CHINESE MEDICINE; CINCHONA; COLCHICUM; DRUG ISOLATION; ETHNOPHARMACOLOGY; HIGH THROUGHPUT SCREENING; MODEL; NONHUMAN; PHYLOGENETIC TREE; PHYLOGENY; REVIEW; SOLANUM; TAXUS BREVIFOLIA; TRADITIONAL MEDICINE;

BIODIVERSITY; PHYLOGENY;

EID: 80054067079     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798109473     Document Type: Review

References (120)

1. Balick MJ, Elisabetsky E, Laird SA. Medicinal resources of the tropical forest: biodiversity and its importance to human health. New York: Columbia University Press 1996.
2. Craig GM, Newman DJ. Discovery and development of antineoplastic agents from natural sources. Cancer Invest 1999; 17: 153-63.
3. Cox PA. Ensuring equitable benefits: the Falealupo covenant and the isolation of anti-viral drug prostratin from a Samoan medicinal plant. Pharm Biol 2001; 39: 33-40.
4. Coley PD, Heller MV, Aizprua R, et al. Using ecological criteria to design plant collection strategies for drug discovery. Front Ecol Environ 2003; 1(8): 421-8.
5. Nicolaou KC, Chen JS, Dalby SM. From nature to the laboratory and into the clinic. Bioorg Med Chem 2009; 17(6): 2290-303.
6. Fransworth NR, Bingel AS. In: Wagner H, Wolff P, Eds. Problems and prospects of discovering new drugs from higher plants by pharmacological screening. Berlin, Springer. 1977; 1-22.
7. Stevenson WG, Friedman PL. In: Hennekens CH, Ed. Clinical trials in cardiovascular disease. Philadelphia, WB Saunders Co. 1999; 217-30.
8. Macilwain C. When rhetoric hits reality in debate on bioprospecting. Nature 1998; 392: 535-40.
9. Soejarto DD. In: Kinghorn AD, Balandrin MF Eds. Logistics and politics in plant drug discovery. Washington, American Chemical Society 1993; 96-111.
10. Gertsch J. How scientific is the science in ethnopharmacology? Historical perspectives and epistemological problems. J Ethnopharmacol 2009; 122(2): 177-83.
11. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003; 66(7): 1022-37.
12. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007; 70(3): 461-77.
13. Li JW, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science 2009; 325(5937): 161-5.
14. Service RF. Surviving the blockbuster syndrome. Science 2004; 303(5665): 1796-9.
15. Garcia P. Discovery by serendipity: a new context for an old riddle. Found Chem 2009; 11: 33-42.
16. Verheij H, Robeson BL. The role of chemical diversity in drug discovery, Genomic/Proteomic Technology-2 September/October 2002; pp 32, 34-35.
17. Baltz RH. Marcel Faber Roundtable: Is our antibiotic pipeline unproductive because of starvation, constipation or lack of inspiration? J Ind Microbiol Biotechnol 2006; 33: 507-13.
18. Taleb NN. Fooled by randomness: the hidden role of chance in life and in the markets. Random house publishing group, 2008.
19. Floyd CD, Leblanc C, Whittaker M. Combinatorial chemistry as a tool for drug discovery. Prog Med Chem 1999; 36: 91-168.
20. Kaiser M, Wetzel S, Kumar K, Waldmann H. Biology-inspired synthesis of compound libraries. Cell Mol Life Sci 2008; 65(7-8): 1186-201.
21. Tan G, Gyllenhaal C, Soejarto DD. Biodiversity as a source of anticancer drugs. Curr Drug Targets 2006; 7(3): 265-77.
22. Liu X, Ashforth E, Ren B, et al. Bioprospecting microbial natural product libraries from the marine environment for drug discovery. J Antibiot (Tokyo) 2010; 63: 415-22.
23. Gani OA, Engh RA. Protein kinase inhibition of clinically important staurosporine analogues. Nat Prod Rep 2010; 27(4): 489-98.
24. Pietra F. Biodiversiy and Natural Product Diversity, 2002, PergamonTetrahedron Organic Chemistry Series, pp 366.
25. Caporale LH. Chemical ecology: A view from the pharmaceutical industry. Proc Natl Acad Sci U S A 1995; 92: 75-82.
26. Harvey AL, Waterman PG. The continuing contribution of biodiversity to drug discovery. Curr Opin Drug Discovery Dev 1998; 1: 71-6.
27. Tulp M, Bohlin L. Functional versus chemical diversity: is biodiversity important for drug discovery? Trends Pharmacol Sci 2002; 23(5): 225-31.
28. Becerra JX, Noge K, Venable DL. Macroevolutionary chemical escalation in an ancient plant-herbivore arms race. Proc Natl Acad Sci U S A 2009; 106(43): 18062-6.
29. Becerra JX. Synchronous coadaptation in an ancient case of herbivory. Proc Natl Acad Sci U S A 2003; 100(22): 12804-7.
30. Becerra JX. Insects on plants: macroevolutionary chemical trends in host use. Science 1997; 276: 253-6.
31. Cordell GA., Quinn-Beattie ML, Farnsworth NR. The potential of alkaloids in drug discovery. Phytother Res 2001; 15(3): 183-205.
32. Douwes E, Crouch NR, Edwards TJ, Mulholland DA. Regression analyses of southern African ethnomedicinal plants: informing the targeted selection of bioprospecting and pharmacological screening subjects. J Ethnopharmacol 2008; 119(3): 356-64.
33. He L, Orr GA, Horwitz SB. Novel molecules that interact with microtubules and have functional activity similar to Taxol. Drug Discovery Today 2001; 6: 1153-64.
34. Altmann KH, Gertsch J. Anticancer drugs from nature-natural products as a unique source of new microtubule-stabilizing agents. Nat Prod Rep 2007; 24: 327-57.
35. Gershenzon J, Dudareva N. The function of terpene natural products in the natural world. Nat Chem Biol 2007; 3: 408-14.
36. Tulp M, Bohlin L. Rediscovery of known natural compounds: Nuisance or goldmine? Bioorg Med Chem 2005; 13: 5274-82.
37. Forbey JS, Harvey AL, Huffman MA, Provenza FD, Sullivan R, Tasdemir D. Exploitation of secondary metabolites by animals: A response to homeostatic challenges. Integr Comp Biol 2009; 49(3): 314-28.
38. McGrath P, Li CQ. Zebrafish: a predictive model for assessing drug-induced toxicity. Drug Discovery Today 2008; 13: 394-401.
39. Lam CS, Rastegar S, Strahle U. Distribution of cannabinoid receptor-1 in the CNS of Zebrafish. Neuroscience 2006; 138: 83-95.
40. Chianese R, Cobellis G, Pierantoni R, Fasano S, Meccariello R. Non-mamalian vertebrate models and the endocannabinoid system: relationships with gonadotropin-releasing hormone. Mol Cell Endocrinol 2008; 286: 846-51.
41. Gertsch J, Pertwee RG, Di Marzo V. Phytocannabinoids beyond the Cannabis plant - do they exist? Br J Pharmacol 2010; 160(3): 523-9.
42. Verpoorte R. Exploration of nature's chemodiversity: the role of secondary metabolites as leads in drug development. Drug Discovery Today 1998; 3: 232-8.
43. Jones CG, Firn RD, Malcolm SB. On the evolution of secondary chemical diversity. Philos Trans R Soc London Ser B 1991; 333: 273-80.
44. Bhakuni DS, Dhar ML, Dhar MM, Dhavan BN, Gupta B, Srimal RC. Screening of Indian plants for biological activity-III. Indian J Exp Biol 1971; 9: 91-102.
45. Suffness M, Douros J. Current status of the NCI plant and animal product program. J Nat Prod 1982; 45: 1-14.
46. Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Perspec 2001; 109: 69-75.
47. Wall ME, Wani MC. Camptothecin and taxol: from discovery to clinic. J Ethnopharmacol 1996; 51: 239-54.
48. Morgan RE, Westwood NJ. Screening and synthesis: high throughput technologies applied to parasitology. Parasitology 2004; 128: 871-9.
49. Pandey RC. Prospecting for potentially new pharmaceuticals from natural sources. Med Res Rev 1998; 18(5): 333-46.
50. Spjut RW. Relationships between plant folklore and antitumor activity: an historical review. Sida 2005; 21(4): 2205-41.
51. Patwardhan B, Vaidya ADB, Chorghade M. Ayurveda and natural products drug discovery. Curr Sci 2004; 86(6): 789-99.
52. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: A comparative overview. eCAM 2005; 2(4): 465-73.
53. Derek L. Merck bails on natural products. Available at: http://pipeline.corante.com/archives/2008/05/08/merck_bails_on_natural_products.php [accessed May 8, 2008].
54. Farnsworth NR. The role of ethnopharmacology in drug development. Ciba Found Symp 1990; 154: 2-11.
55. Farnsworth NR. Ethnopharmacology and drug development. Ciba Found Symp 1994; 185: 42-51.
56. Hamilton GR, Baskett TF. In the arms of Morpheus: the development of morphine for postoperative pain relief. Can J Anaesth 2000; 47: 367-74.
57. Sneader W. Drug prototypes and their exploitation. UK; Wiley. 1996.
58. Pelletier PS, Caventon J. [Title unknown]. Ann. Chim. Phys 1820; 14: 69.
59. Gerhardt C. Untersuchungen über die wasserfreien organischen Säuren. Annalen der Chemie und Pharmacie 1853; 87: 149-79.
60. McKenzie AG. The rise and fall of Strophanthin. International Congress Series 2002; 1242: 95-100.
61. Farnsworth NR, Akerele O, Bingel AS, Soejarto DD, Guo Z. Medicinal plants in therapy. Bull World Health Organ 1985; 63(6): 965-81.
62. Slish DF, Ueda H, Arvigo R, Balick MJ. Ethnobotany in the search for vasoactive herbal medicines. J Ethnopharmacol 1999; 66 (2): 159-165.
63. Carvalho LH, Kettli AU. Antimalarial chemotherapy with natural products and chemically defined molecules. Mem Inst Oswaldo Cruz 1991; 86(2): 181-4.
64. Cox PA, Balick MJ. The ethnobotanical approach to drug discovery. Sci Am 1994; 270(6): 82-7.
65. Spjut RW, Perdue RE Jr. Plant folklore: a tool for predicting sources of antitumor activity? Cancer Treat Rep 1976; 60(8): 979-85.
66. McManus OB, Harris GH, Glangiacorno KM, et al. An activator of calcium-dependent potassium channels isolated from a medicinal herb. Biochemistry 1993; 32: 6128-33.
67. Hamburger M, Hostettmann K. Bioactivity in plants: the link between phytochemistry and medicine. Phytochemistry 1991; 30: 3864-74.
68. Cox PA. In: Chadwick DJ, Marsh J Eds, The ethnobotanical approach to drug discovery: strengths and limitations. Ciba Found Symp. Chichester, United Kingdom. John Wiley & Sons. 1994; 25-36, discussion 36-41.
69. Khafagi IK, Dewedar A. The efficiency of random versus ethno- directed research in the evaluation of Sinai medicinal plants for bioactive compounds. J Ethnopharmacol 2000; 71(3): 365-76.
70. Cordell GA, Colvard MD. Some thoughts on the future of ethnopharmacology. J Ethnopharmacol 2005; 100: 5-14.
71. Cordell GA. Changing strategies in natural product chemistry. Phytochemistry 1995; 40(6): 1585-1612.
72. Chin YW, Balunas MJ, Chai HB, Kinghorn AD. Drug discovery from natural sources. AAPS J 2006; 8(2): E239-53.
73. Thurston EL, Lersten NR. The morphology and toxicology of plant stinging hairs. Bot Rev 2008; 35(4): 393-412.
74. Fu HY, Chen SJ, Chen RF, Ding WH, Kuo-Huang LL, Huang RN. Identification of oxalic acid and tartaric acid as major persistent pain-inducing toxins in the stinging hairs of the nettle, Urtica thunbergiana. Ann Bot 2006; 98: 57-65.
75. Alves RRN, Rosa IML. Biodiversity, traditional medicine and public health: where do they meet? J Ethnobiol Ethnomed 2007; 3: 14.
76. Uma Shaanker R, Ravishankar KV, Ganeshaiah KN. Why do plants posses laxatives? Curr Sci. 1997; 73(8): 646-7.
77. Ebadi MS. Pharmacodynamic basis of herbal medicine. CRC Press, 2007.
78. Gunawardene NR. et al. A brief overview of the Western Ghats-Sri Lanka biodiversity hotspot. Curr Sci 2007; 93(11): 1567-72.
79. Hebbar R, Sashidhar VR, Uma Shaanker R, Udaya Kumar M, Sudarshana L. Dispersal mode of species influences the trypsin inhibitor levels in fruits. Naturwissenschaften 1993; 80: 519-21.
80. Lokesha R, Hegde SG, Uma Shaanker R, Ganeshaiah KN. Dispersal mode as a selective force in shaping chemical composition of seeds. Am Nat 1992; 140(3): 520-5.
81. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. Jpn J Antibiot 1976; 29: 1346-8.
82. Stossel TP. The discovery of statins. Cell 2008; 134(6): 903-5.
83. Bloch K, Rittenberg D. On the utilization of acetic acid for cholesterol formation. J Biol Chem 1942; 145: 625-36.
84. Bloch K. The biological conversion of cholesterol to pregnanediol. J Biol Chem 1945; 157: 661-6.
85. Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discovery 2003; 2: 517-26.
86. Hawkey C. Plasminogen activator in the saliva of the vampire bat Desmodus rotundus. Nature 1966; 211: 434-5.
87. Schleuninh WD. Vampire bat plasminogen activator DSPA-Alpha- 1(Desmoteplase): A thrombolytic drug optimized by natural selection. Haemostasis 2001; 31: 118-22.
88. Lafuma L, Lambrechts MM, Raymond M. Aromatic plants in bird nests as a protection against blood sucking flying insects. Behav Processes 2001; 56: 113-20.
89. Oh DC, Poulsen M, Currie CR, Clardy J. Dentigerumycin: a bacterial mediator of an ant-fungus symbiosis. Nat Chem Biol 2009; 5: 391-3.
90. Kroiss J, Kaltenpoth M, Schneider B, et al. Symbiotic Streptomycetes provide antibiotic combination prophylaxis for wasp offspring. Nat Chem Biol 2010; 6: 261-3.
91. Chernysh S, Kim SI, Bekker G, et al. Antiviral and antitumor peptides from insects. Proc Natl Acad Sci U S A 2002; 99(20): 12628-32.
92. Chandrashekara K, Jayappa J, Kumar ARV. Insects as source of novel antimicrobial peptides: towards an ecological and evolutionary rationale for bioprospecting insects. International Symposium on Innnovative Agricultural Biotechnology, Oct 5-9, 2009, National Pingtung University, Pingtung, Taiwan.
93. Christel CM, DeNardo DF, Secor SM. Metabolic and digestive response to food ingestion in a binge-feeding lizard, the Gila monster (Heloderma suspectum). J Exp Biol 2007; 210(19): 3430-9.
94. Mason EE. Gila monster's guide to surgery for Obesity and Diabetes. J Am Coll Surg 2008; 206(2): 357-60.
95. Beattie AJ, Ehrlich PR. Wild solutions: how biodiversity is money in the bank. New Haven, CT: Yale University Press 2001.
96. Wynne-Edwards EK. Evolutionary biology of plant defences against herbivory and their predictive implications for endocrine disruptor susceptibility in vertebrates. Environ Health Perspect 2001; 109(5): 443-8.
97. Müller WE, Schröder HC, Wiens M, Perović-Ottstadt S, Batel R, Müller IM. Traditional and modern biomedical prospecting: Part II- the benefits: approaches for a sustainable exploitation of biodiversity (Secondary Metabolites and Biomaterials from Sponges). Evid Based Complement Alternat Med 2004; 1(2): 133-44.
98. Dahlgren RMT, Rosendal-Jensen S, Nielsen BJ. In: Young DA, Seigler DS, Eds. A revised classification of the angiosperms with comments on correlation between chemical and other characters. NY, Praeger, 1981; 149-204.
99. Wink M. Evolution of secondary metabolites from an ecological and molecular phylogenetic perspective. Phytochemistry 2003; 64: 3-19.
100. Kingston DGI. Recent advances in the chemistry of Taxol. J Nat Prod 2000; 63: 726-34.
101. Smith WL, Wheeler WC. Venom evolution widespread in Fishes: a phylogenetic road map for the bioprospecting of Piscine venoms. J Hered 2006; 97(3): 206-17.
102. Cronquist A. The evolution and classification of flowering plants. New York Botanical Garden, NY, USA 1988.
103. Thompson SK, Seber GAF. Adaptive Sampling. John Wiley and Sons, Inc., New York, 1996.
104. THE ANGIOSPERM PHYLOGENY GROUP. An update of the Angiosperm Phylogeny Group classification for the orders and families of flowering plants: APG III. Bot J Linn Soc 2009: 161: 105-21.
105. Muller WEG, Batel R, Schröder HC, Muller IM. Traditional and modern biomedical prospecting: Part I-the history and sustainable exploitation of biodiversity (Sponges and Invertebrates) in the Adriatic Sea in Rovinj (Croatia). Evid Based Complement Alternat Med 2004; 1(1): 71-82.
106. Warr WA, Some Trends in Chem(o)informatics. Methods Mol Biol 2011; 672: 1-37.
107. Markt P, Feldmann C, Rollinger JM, et al. Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem 2009; 52(2): 369-78.
108. Rollinger JM, Schuster D, Danzl B, et al. In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens. Planta Med 2009; 75(3): 195-204. Erratum in: Planta Med 2009; 75(3): 293.
109. Nguyen KT, Syed S, Urwyler S, Bertrand S, Bertrand D, Reymond JL. Discovery of NMDA glycine site inhibitors from the chemical universe database GDB. ChemMedChem 2008; 3(10): 1520-4.
110. Wagner BK, Clemons PA. Connecting synthetic chemistry decisions to cell and genome biology using small-molecule phenotypic profiling. Curr Opin Chem Biol 2009; 13(5-6): 539-48.
111. Srirama R, Ramesha BT, Ravikanth G, Uma Shaanker R, Ganeshaiah KN. Are plants with anti-cancer activity resistant to crown gall?: A test of hypothesis. Curr Sci 2008; 95: 1407-8.
112. Baek KH, Zaslavsky A, Lynch RC, et al. Down's syndrome suppression of tumor growth and the role of the calcineurin inhibitor DSCR1. Nature. 2009; 459(7250): 1126-30.
113. Epstein RJ. Unblocking blockbusters: Using Boolean text-mining to optimize clinical trial design and timeline for novel anticancer drugs. Cancer Informatics 2009; 7: 231-8.
114. Fleming A. Penicillin, Nobel Lecture, 11 Dec 1945. In Nobel Lectures: Physiology or Medicine 1942-1962 (1964), 83.
115. Nelson L. Venomous snails: One slip and you're dead. Nature 2004; 429: 798-9.
116. Bachmann BO. Decoding chemical structures from genomes. Nat Chem Biol 2005; 1: 244-5.
117. Kita M, Nakamura Y, Okumura Y, et al. Blarina toxin, a mammalian lethal venom from the short-tailed shrew Blarina brevicauda: Isolation and characterization. Proc Natl Acad Sci USA 2007; 101: 7542-7.
118. Brahmachary RL, Sarkar MP, Dutta J. The aroma of rice and tiger. Nature 1990; 344: 26.
119. Triggle DJ. The chemist as astronaut: Searching for biologically useful space in the chemical universe. Biochem Pharmacol 2009; 78(3): 217-23.
120. Rausser G, Small A. Valuing research leads: bioprospecting and the conservation of genetic resources. J Polit Econ 2000; 108(1): 173-206.